Artielle ImmunoTherapeutics Receives $100,000 New Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6381f172-2566-47dc-abcc-cb2f8b18d639&Preview=1 -
Date
9/9/2010 -
Company Name
Artielle ImmunoTherapeutics -
Mailing Address
9020 SW Washington Square Road Tigard, OR 97223 -
Company Description
Artielle ImmunoTherapeutics’ technology is focused on a new proprietary class of molecules known as Recombinant T cell receptor Ligands (RTLs) that can be tailored to treat a wide range of autoimmune diseases. Artielle has developed a lead compound for the treatment of multiple sclerosis, called RTL1000, which is in Phase 1 clinical trials and has received Orphan Drug status from the U.S. Food and Drug Administration. -
Website
http://www.artielle.com -
Transaction Type
Debt -
Transaction Amount
$100,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. -
M&A Terms
-
Venture Investor
Undisclosed
